Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Association between JAK2 V617F-Clonal Hematopoiesis of Indeterminate Potential and Microthromboembolism-Related Diseases

Chih-Cheng Chen, Ying-Hsuan Wang, Cih-En Huang, Yi-Yang Chen

Blood (2024) 144 (Supplement 1): 5643.

https://doi.org/10.1182/blood-2024-202889

Published: 2024

Journal Articles

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Peter Tan, Ross Baker, Sung-Eun Lee, Anne Marie Watson, Stanley Cheung, Shang-Ju Wu, Chih-Cheng Chen, Shuhying Tan, Pankit Vachhani, Tsai-Yun Chen, Jae Hoon Lee, Hui-Hua Hsiao, Ji Yun Lee, Won Sik Lee, Lucia Masarova, Jana Baskar, Wolfgang Jarolimek, Joanna Leadbetter

Blood (2024) 144 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2024-204290

Published: 2024

Journal Articles

Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification

Harinder Gill, Lester Au, Garret Man Kit Leung, Dorothy Tsai, Rita Yim, Lynn Chin, Vivian Li, Paul Lee, Albert Chun Fung Sin, Hsin An Hou, Chih-Cheng Chen, Yok Lam Kwong

Blood (2023) 142 (Supplement 1): 4562.

https://doi.org/10.1182/blood-2023-180922

Published: 2023

Journal Articles

Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis

Harinder Gill, Lester Au, Rita Yim, Lynn Chin, Vivian Li, Paul Lee, Garret MK Leung, Carmen Lee, Tony Kwun Yat Wu, Cheong Ngai, Ryan Ho, Albert Chun Fung Sin, Hsin-An Hou, Chih-Cheng Chen, Yok-Lam Kwong

Blood (2022) 140 (Supplement 1): 1522.

https://doi.org/10.1182/blood-2022-169613

Published: 2022

Journal Articles

Treatment of Ropeginterferon Alpha-2b Achieves Hematologic Remission and Molecular Response in Patients with Hydroxyurea- and/or Anagrelide-Resistant/Intolerant Myeloproliferative Neoplasms

Chih-Cheng Chen, Ming-Chung Kuo, Yi-Jiun Su, Cih-En Huang, Chia-Chen Hsu, Yu-Ying Wu, Ying-Ju Chen, Lee-Yung Shih

Blood (2021) 138 (Supplement 1): 4631.

https://doi.org/10.1182/blood-2021-147746

Published: 2021

Journal Articles

Single-Cell RNA Sequencing Discloses Distinct Transcriptomic Profiling in Essential Thrombocythemia

Chia-Chen Hsu, PhD, Cih-En Huang, MD, Ying-Ju Chen, Yuying Wu, MD, Hsing-Yi Tsou, Chian-Pei Li, Wei-Hsuan Chuang, Yi-Hua Lai, Yi-Hsuan Lin, Chih-Cheng Chen, MD

Blood (2018) 132 (Supplement 1): 3061.

https://doi.org/10.1182/blood-2018-99-113990

Published: 2018

Journal Articles

Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

Yi-Jiun Su, MD, Ming-Chung Kuo, MD, Chieh-Lin Teng, MD, Tsai-Yun Chen, MD, Ming-Chun Ma, MD, Pei-Ching Hsiao, MD, Ming-Chung Wang, MD, Tung-Huei Lin, MS, Wen-Li Hwang, MD, Chih-Cheng Chen, MD, Youngsen Yang, MD, Sung-Nan Pei, MD, Yen-Min Huang, MD, Sin-Syue Li, MD, Ming-Yang Lee, MD, Hung-I Cheng, MD, Lee-Yung Shih, MD

Blood (2017) 130 (Supplement 1): 1603.

https://doi.org/10.1182/blood.V130.Suppl_1.1603.1603

Published: 2017

Journal Articles

Aberrant Let7a/HMGA2 Signaling Axis with Unique Clinical Phenotype in JAK2 -Mutated Myeloproliferative Neoplasms

Chia-Chen Hsu, PhD, Chih-Cheng Chen, MD PhD, Jyh-Pyng Gau, MD PhD, Cih-En Huang, MD, Jie-Yu You, MD PhD, Jrhau Lung, PhD, YI-Yang Chen, Hsing-Ying Ho, MS, Chian-Pei Li, MS, Chang-Hsien Lu, MD, Kuan-Der Lee, MD PhD

Blood (2016) 128 (22): 5492.

https://doi.org/10.1182/blood.V128.22.5492.5492

Published: 2016

Journal Articles

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Ming-Chung Kuo, MD, Tsai-Yun Chen, MD, Ming-Chung Wang, MD, Youngsen Yang, MD, Su-Peng Yeh, MD, Cheng-Shyong Chang, MD, Yii-Jenq Lan, MD, Chih-Cheng Chen, MD, Yu-Chieh Su, MD, Pei-Ching Hsiao, MD, Ching-Yuan Kuo, MD, Li-Yuan Bai, MD, Wen-Li Hwang, MD, Lee-Yung Shih, MD

Blood (2014) 124 (21): 4544.

https://doi.org/10.1182/blood.V124.21.4544.4544

Published: 2014

Journal Articles

Favorable Clinical Outcome and Unique Characteristics in Association with Twist1 overexpression in De Novo Acute Myeloid Leukemia

Cih-En Huang, MD, Chih-Cheng Chen, MDPhD, Jyh-Pyng Gau, MD, Jie-Yu You, MD, Yi-Yang Chen, MD, Hui-Ju Chou, Jrhau Lung, Muh-Hwa Yang, MD

Blood (2014) 124 (21): 5263.

https://doi.org/10.1182/blood.V124.21.5263.5263

Published: 2014

Journal Articles

The 46/1 Haplotype Frequency Is Not Increased in Patients of Essential Thrombocythemia with CALR Mutations

Jyh-Pyng Gau, MD, Chih-Cheng Chen, MDPhD, Chia-Jen Liu, MD, Yuan-Bin Yu, MD, Liang-Tsai Hsiao, MD, Jin-Hwang Liu, MD PhD, Po-Min Chen, MD PhD, Cheng-Hwai Tzeng, MD

Blood (2014) 124 (21): 5204.

https://doi.org/10.1182/blood.V124.21.5204.5204

Published: 2014

NARROW

Association between JAK2 V617F-Clonal Hematopoiesis of Indeterminate Potential and Microthromboembolism-Related Diseases

Multicenter, Open-Label Phase 1/2a Study of Pxs-5505 and Ruxolitinib in Patients with Primary, Post-Polycythemia Vera (PV) or Post-Essential Thrombocythemia (ET) Myelofibrosis

Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis: Durable Responses and Evidence of Disease Modification

Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis

Treatment of Ropeginterferon Alpha-2b Achieves Hematologic Remission and Molecular Response in Patients with Hydroxyurea- and/or Anagrelide-Resistant/Intolerant Myeloproliferative Neoplasms

Single-Cell RNA Sequencing Discloses Distinct Transcriptomic Profiling in Essential Thrombocythemia

Comparison of Molecular Responses between e14a2 and e13a2 BCR-ABL1 Transcripts in Patients with Chronic Myeloid Leukemia in Chronic Phase Treated with Front-Line Second Generation Tyrosine Kinase Inhibitors: Taiwan CML Study

Aberrant Let7a/HMGA2 Signaling Axis with Unique Clinical Phenotype in JAK2 -Mutated Myeloproliferative Neoplasms

No Differences in Outcomes Between Patients Achieving Early Molecular Response at 3 Months and Those Achieving Optimal Response at 6 or 12 Months in Chronic Phase of Chronic Myeloid Leukemia Treated with Front-Line Imatinib: Taiwan CML Study

Favorable Clinical Outcome and Unique Characteristics in Association with Twist1 overexpression in De Novo Acute Myeloid Leukemia

The 46/1 Haplotype Frequency Is Not Increased in Patients of Essential Thrombocythemia with CALR Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only